Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01977781 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy of Topical Tacrolimus 0.05% in the Treatment of Ocular Graft-Versus-Host Disease
A Phase 1 study, sponsored by Massachusetts Eye and Ear Infirmary.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT01977781 is a Phase 1 study that has completed, run by Massachusetts Eye and Ear Infirmary. The registered enrollment target is 40 participants.
The verdict
NCT01977781, a Phase 1 study, has completed, sponsored by Massachusetts Eye and Ear Infirmary.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and tolerability of topical tacrolimus 0.05% twice a day in the treatment of ocular graft versus host disease (GVHD).
Interventions
- DRUG Tacrolimus
- DRUG Methylprednisolone Sodium Succinate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2013-12 |
| Est. Completion | 2014-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01977781
The ClinicalTrials.gov registry entry for NCT01977781 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts Eye and Ear Infirmary, which has 73 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Tacrolimus is the first listed.
NCT01977781 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01977781 about?
NCT01977781 is a clinical study titled "Safety and Efficacy of Topical Tacrolimus 0.05% in the Treatment of Ocular Graft-Versus-Host Disease". The purpose of this study is to evaluate the safety and tolerability of topical tacrolimus 0.05% twice a day in the treatment of ocular graft versus host disease (GVHD).
What is the current status of trial NCT01977781?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2013-12. Estimated completion is 2014-09.
What interventions are being tested in trial NCT01977781?
The interventions under investigation include: Tacrolimus (DRUG), Methylprednisolone Sodium Succinate (DRUG).
Who is sponsoring clinical trial NCT01977781?
This trial is sponsored by Massachusetts Eye and Ear Infirmary, which has 73 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.